Shots:

• The company launches Alymsys, a biosimilar referencing Avastin to provide additional access and options to patients and physicians for affordable oncology treatments
• Alymsys is a vascular endothelial growth factor inhibitor used in oncology that was developed by mAbxience with an experience in the development, manufacture, and commercialization of biopharmaceuticals
• Additionally, the company also seeks to increase the number of molecules in its biosimilar portfolio and has a growing line of branded pharmaceutical products with a primary focus on endocrine and central nervous system disorders

Ref: Businesswire | Image: Amneal